Baidu
map

Lancet:死亡风险到底归因于极冷还是极热?

2015-05-26 范伟译 MedSci原创

背景:在选定的国家中,尽管研究提供过早死亡归因于热或冷,但到目前为止暴露于不同气候的人群整个温度范围内没有提供系统的评估。我们旨在量化总死亡率的负担,归因于非最适宜的环境温度,来自冷和热,适中的和极端的温度的相对影响。方法:我们收集的数据来自澳大利亚、巴西、加拿大、中国、意大利、日本、韩国、西班牙、瑞典、台湾、泰国、英国和美国的384个地点。我们为每个地点设置一个时间序列泊松回归模型,控制每周的趋

背景:在选定的国家中,尽管研究提供过早死亡归因于热或冷,但到目前为止暴露于不同气候的人群整个温度范围内没有提供系统的评估。我们旨在量化总死亡率的负担,归因于非最适宜的环境温度,来自冷和热,适中的和极端的温度的相对影响。

方法:我们收集的数据来自澳大利亚、巴西、加拿大、中国、意大利、日本、韩国、西班牙、瑞典、台湾、泰国、英国和美国的384个地点。我们为每个地点设置一个时间序列泊松回归模型,控制每周的趋势和天数。我们估测温度-死亡率的关联,采用21天延迟的分布滞后的非线性模型,然后把他们汇集在多元meta回归分析中包括国家指标,平均温度和范围。我们计算冷和热的归因死亡,定义之上和之下的最适宜温度,其与最低死亡率相一致,对于中等的和极端的温度,使用2.5th和97.5th温度百分位数截止。 



结果:在1985年和2012年之间各个时期,我们分析了74 225200名死亡的人。在选定国家的研究期间内,总共7.71%(95% 实证的CI 7.43-7.91)的死亡率可归因于非最适宜的温度,国家之间有着显著的差异,从泰国的3.37%(3.06 - 3.63)到中国的 11.00%(9.29 - 12.47)。最低死亡率温度的百分比从热带地区大约60th百分位数变化到温带地区大约80 -90th百分位数。更多的归因温度的死亡是由于冷(7.29%,7.02-7.49)而不是由于热(0.42%,0.39-0.44)。极端的冷热气温造成了0.86%(0.84 - 0.87)的总死亡率。

结论:大部分跟温度有关的死亡率过重可归因于寒冷的原因。极端温度的影响实质上低于中等的天气但非最适宜的天气。这个证据对公共卫生干预措施的规划具有重要影响,将不良温度的健康影响降到最低,在气候变化情况下预测未来的可能影响后果。 


原始出处:

Gasparrini A1, Guo Y2, Hashizume M3, Lavigne E4, Zanobetti A5, Schwartz J5,
Tobias A6, Tong S7, Rocklöv J8, Forsberg B8, Leone M9, De Sario M9, Bell ML10,
Guo YL11, Wu CF12, Kan H13, Yi SM14, de Sousa Zanotti Stagliorio Coelh M15,
Saldiva PH15, Honda Y16, Kim H14, Armstrong B17.Mortality risk attributable to
high and low ambient temperature: a multicountry observational study
.
Lancet. 2015 May 19. pii: S0140-6736(14)62114-0.
全文下载:PDF (360 KB)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1828119, encodeId=26b91828119a5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Mar 02 00:03:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28825, encodeId=8dd52882538, content=都不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 09:44:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25628, encodeId=d4bd25628ed, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:34:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25414, encodeId=a36b2541439, content=这个研究厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Sat May 30 15:55:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255516, encodeId=1ca41255516a3, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu May 28 12:03:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
    2016-03-02 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1828119, encodeId=26b91828119a5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Mar 02 00:03:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28825, encodeId=8dd52882538, content=都不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 09:44:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25628, encodeId=d4bd25628ed, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:34:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25414, encodeId=a36b2541439, content=这个研究厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Sat May 30 15:55:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255516, encodeId=1ca41255516a3, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu May 28 12:03:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
    2015-06-25 nizongzan

    都不好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1828119, encodeId=26b91828119a5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Mar 02 00:03:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28825, encodeId=8dd52882538, content=都不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 09:44:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25628, encodeId=d4bd25628ed, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:34:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25414, encodeId=a36b2541439, content=这个研究厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Sat May 30 15:55:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255516, encodeId=1ca41255516a3, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu May 28 12:03:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
    2015-05-31 huaxipanxing

    看看

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1828119, encodeId=26b91828119a5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Mar 02 00:03:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28825, encodeId=8dd52882538, content=都不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 09:44:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25628, encodeId=d4bd25628ed, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:34:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25414, encodeId=a36b2541439, content=这个研究厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Sat May 30 15:55:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255516, encodeId=1ca41255516a3, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu May 28 12:03:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
    2015-05-30 lovejing

    这个研究厉害

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1828119, encodeId=26b91828119a5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Mar 02 00:03:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28825, encodeId=8dd52882538, content=都不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 09:44:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25628, encodeId=d4bd25628ed, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:34:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25414, encodeId=a36b2541439, content=这个研究厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Sat May 30 15:55:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255516, encodeId=1ca41255516a3, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu May 28 12:03:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]

相关资讯

Diabetes Care:1型糖尿病患者发生心血管事件后死亡风险增加

澳大利亚联合瑞典的一项研究表明,既往有过严重低血糖事件的1型糖尿病患者在发生心血管事件后死亡风险增加。相关论文8月4日在线发表于《糖尿病护理》(Diabetes Care)杂志。 该研究是基于瑞典国家糖尿病登记库相关数据和记录,入选了2002–2010门诊1型糖尿病患者,这些患者在门诊看病之后均经历了严重的心血管并发症。研究者们用二部模型评估患者发生心血管事件后的全因死亡率。在既往有或无

JACC:地高辛增房颤者死亡风险添新证

一项在新诊断心房颤动(以下简称房颤)老年退伍人群中进行的大型队列研究显示,那些接受初始地高辛治疗的患者的3年内死亡风险增加>20%,这种风险增加独立于年龄,性别,心力衰竭(以下简称心衰),肾功能或β阻滞剂、胺碘酮和华法林的联合应用。相关论文8月11日在线发表于《美国心脏病学会杂志》(Journal of the American College of Cardiology,简称JACC)

Lancet:DAPT个体化治疗死亡风险分析

最近研究显示,在冠状动脉药物洗脱支架置入后双重抗血小板治疗(DAPT)的最佳时间仍然不确定。我们进行了一项荟萃分析评价了死亡率和其他临床结果。 我们在线检索了Medline, Embase, Cochrane databases和国际会议2011年12月16日至2014年11月16日之间发表文章,我们收纳了10项试验(n=31666)并对这些研究进行了荟萃分析。每项研究中DAPT治疗时间可以是6

JACC:每天跑跑步,死亡风险低

最近一项发表在《美国心脏病学会期刊》(Journal of the American College of Cardiology)上的研究显示,相比于那些从来不跑步的人来说,每天只跑步几分钟或者只是慢跑也能显著降低人们因心血管疾病死亡的风险。众所周知,锻炼能够预防心脏疾病的发生,同时它也是健康生活不可或缺的一部分。美国政府以及世界卫生组织建议每周进行75分钟的高强度运动(比如跑步),但如果锻炼时间

BMJ:克拉霉素或增心脏病风险

抗生素--克拉霉素,广泛用于治疗常见的细菌性感染。刊登在BMJ杂志的一项研究证实:克拉霉素的使用与心脏疾病死亡风险增加相关。研究人员表示:他们的研究发现需要被紧急确认验证,因为每年数以百万计的人使用该药。但他们强调,克拉霉素增加心脏疾病死亡风险的绝对风险是很小的,除非研究结果在一个独立的研究得到证实,因此没有必要过分担心。 克拉霉素属于大环内酯类抗生素,大环内酯类抗生素延长心脏肌肉的电活动持

JASN:高透析率β阻滞剂或增透析者死亡风险

β受体阻滞剂一般用于透析患者减少心脏猝死风险。近期加拿大学者进行了相关研究。结果表明,在长期血液透析患者中,与低透析率β受体阻滞剂相比,高透析率β受体阻滞剂可能导致死亡风险显著升高。论文10月30日在线发表于《美国肾脏病学会杂志》(J Am Soc Nephrol)。 此项基于人群的回顾性队列研究共纳入6588例长期接受透析治疗的受试者,其中β阻滞剂高、低透析率组各纳入3294例患者,该

Baidu
map
Baidu
map
Baidu
map